QURE ▼ -54.1% - uniQure N.V.
$QURE - uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
29-SEP-2026 07:12 AM ET
Share this post
More filings for $QURE
QURE ▲ +5.1% - uniQure N.V.Sep 2, 2026QURE - uniQure N.V. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026QURE - uniQure N.V. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$QURE SEC Filing Update (20-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 20, 2026$QURE SEC Filing Update (16-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 16, 2026
View full $QURE filing history →💬 Comments
Loading comments…
Leave a comment